VAXXINITY INC-A (VAXX) Stock News
NASDAQ:VAXX - Nasdaq - US92244V1044 - Common Stock - Currency: USD
VAXX Latest News, Press Relases and Analysis
Vaxxinity UB-312 Parkinson’s Trial Results Published in Nature Medicine
UB-312 is the first Parkinson's candidate to reduce pathology as measured by a seed amplification assay, and suggest clinical improvement on motor...
Vaxxinity UB-312 Parkinson’s Trial Results Published in Nature Medicine
Why Is CF Bankshares (CFBK) Stock Down 19% Today?
CF Bankshares stock is falling on Friday after the company launched a public offering for CFBK shares during early morning trading.
Why Is Sprout Social (SPT) Stock Down 32% Today?
Sprout Social stock is down on Friday as SPT investors react to a revenue miss in Q1 and its weak guidance for the full year of 2024!
Why Is Vaxxinity (VAXX) Stock Up 39% Today?
Vaxxinity stock is rising higher on Friday with heavy trading of VAXX shares as it remains volatile ahead of its delisting next week.
Mentions: HSDT
Why Vaxxinity (VAXX) Shares Are Volatile Today
Vaxxinity shares are trading lower by 14% during Tuesday's session. The company recently announced its intention to voluntarily delist and deregister its Class A common stock.
Why Is Vaxxinity (VAXX) Stock Down 58% Today?
Vaxxinity stock is falling hard on Monday after the company announced plans to voluntarily delist shares of VAXX stock next month.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Pre-market stock movers are worth checking out this morning as we dive into all of the biggest news moving shares on Friday!
Vaxxinity Issues Shareholder Letter
CAPE CANAVERAL, Fla., April 19, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (“Vaxxinity”, “we”, “us” or the “Company”) (Nasdaq: VAXX), a U.S. company...
VAXX Stock Earnings: Vaxxinity Beats EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Vaxxinity (NASDAQ:VAXX) just reported results for the fourth quarter of 2023.Va...
VAXX Stock Earnings: Vaxxinity Beats EPS for Q4 2023
VAXX stock results show that Vaxxinity beat analyst estimates for earnings per share the fourth quarter of 2023.
Nike Layoffs 2024: What to Know About the Latest Nike Job Cuts
Nike layoffs are on the way as the athletic wear company is preparing to cut 740 jobs in two rounds at its global headquarters.
Why Is Hepion Pharmaceuticals (HEPA) Stock Down 41% Today?
Hepion Pharmaceuticals stock is falling on Monday as investors in HEPA learn of the company winding down a Phase 2b clinical trial.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
It's time to start ofd the trading week with a look at the biggest pre-market stock movers traders need to watch on Monday morning!
Vaxxinity Issues Shareholder Letter
Vaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common Stock
Vaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common Stock
CAPE CANAVERAL, Fla., April 19, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (“Vaxxinity”, “we”, “us” or the “Company”) (Nasdaq: VAXX), a U.S. company...
Vaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual Meeting
Presentation will address the Company’s clinical data in Parkinson’s disease
Vaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual Meeting
Presentation will address the Company’s clinical data in Parkinson’s disease
Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updates
Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updates
CAPE CANAVERAL, Fla., March 27, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of...
Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson’s Disease at AD/PD™ 2024
UB-312 is first immunotherapy to show reduction of pathological alpha-synuclein in cerebrospinal fluid of Parkinson’s patients
Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson’s Disease at AD/PD™ 2024
UB-312 is first immunotherapy to show reduction of pathological alpha-synuclein in cerebrospinal fluid of Parkinson’s patients...